Auto-antibodies to β-F1-ATPase and vimentin in malignant mesothelioma

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Creaney, Jenette ^a,b   Dick, Ian M ^a   Yeoman, Deborah ^a   Wong, Sarah ^a   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA F1 ATPASE; BETA F1 ATPASE ANTIBODY; CANCER ANTIBODY; PROTEIN ANTIBODY; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG; VIMENTIN; VIMENTIN ANTIBODY; ATP5B PROTEIN, HUMAN; AUTOANTIBODY; CELL EXTRACT;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER CELL; CANCER SCREENING; CANCER SURVIVAL; CELL LYSATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PROGNOSIS; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TISSUE MICROARRAY; WESTERN BLOTTING; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; ENZYMOLOGY; IMMUNOLOGY; MESOTHELIOMA; MIDDLE AGED; MOLECULAR GENETICS; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; SURVIVAL; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; AUTOANTIBODIES; BLOTTING, WESTERN; CELL EXTRACTS; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MOLECULAR SEQUENCE DATA; PROGNOSIS; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; SURVIVAL ANALYSIS; VIMENTIN;

EID: 80054728087     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026515     Document Type: Article

References (36)

1. Robinson BW, Musk AW, Lake RA, (2005) Malignant mesothelioma. Lancet 366: 397-408.
2. Robinson BW, Lake RA, (2005) Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603.
3. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, et al. (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616.
4. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, et al. (2007) Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 132: 1239-1246.
5. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, et al. (2010) Serum Mesothelin for Early Detection of the Asbestos-Induced Cancer Maligant Mesothelioma. Cancer Epidemiol Biomarkers Prev.
6. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, et al. (2008) Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3: 851-857.
7. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, et al. (2008) Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer 98: 1562-1569.
8. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, et al. (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13: 2928-2935.
9. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, et al. (2009) Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 42: 1046-1050.
10. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, et al. (2010) Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181: 620-625.
11. Tan EM, Zhang J, (2008) Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 222: 328-340.
12. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, et al. (2010) Clinical validation of an autoantibody test for lung cancer. Ann Oncol.
13. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, et al. (2010) Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 16: 3452-3462.
14. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94: 1914-1918.
15. Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, et al. (2000) Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 22: 550-556.
16. Robinson C, Robinson BW, Lake RA, (1998) Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 20: 175-184.
17. Grennan Jones F, Ziemnicka K, Sanders J, Wolstenholme A, Fiera R, et al. (1999) Analysis of autoantibody epitopes on human thyroid peroxidase. Autoimmunity 30: 157-169.
18. Ordonez NG, (2003) The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27: 1031-1051.
19. Mewar D, Wilson AG, (2006) Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother 60: 648-655.
20. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, et al. (2007) Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 170: 1415-1427.
21. Mathupala SP, Ko YH, Pedersen PL, (2010) The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797: 1225-1230.
22. Cuezva JM, Sanchez-Arago M, Sala S, Blanco-Rivero A, Ortega AD, (2007) A message emerging from development: the repression of mitochondrial beta-F1-ATPase expression in cancer. J Bioenerg Biomembr 39: 259-265.
23. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaría G, et al. (2002) The Bioenergetic Signature of Cancer. Cancer Research 62: 6674-6681.
24. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, et al. (2005) Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26: 2095-2104.
25. Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, et al. (2004) The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 25: 1157-1163.
26. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, et al. (2010) Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 285: 25308-25313.
27. Lin PC, Lin JK, Yang SH, Wang HS, Li A, et al. (2008) Expression of β-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. International Journal of Colorectal Disease 23: 1223-1232.
28. Chi SL, Pizzo SV, (2006) Cell surface F1Fo ATP synthase: A new paradigm? Annals of Medicine 38: 429-438.
29. Vantourout P, Martinez LO, Fabre A, Collet X, Champagne E, (2008) Ecto-F1-ATPase and MHC-class I close association on cell membranes. Molecular Immunology 45: 485-492.
30. Vacirca D, Delunardo F, Matarrese P, Colasanti T, Margutti P, et al. (2010) Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease. Neurobiol Aging.
31. Veitonmaki N, Cao R, Wu LH, Moser TL, Li B, et al. (2004) Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res 64: 3679-3686.
32. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, et al. (2008) Targeting Therapy for Breast Carcinoma by ATP Synthase Inhibitor Aurovertin B. Journal of Proteome Research 7: 1433-1444.
33. Scotet E, Martinez LO, Grant E, Barbaras R, Jenö P, et al. (2005) Tumor Recognition following V[gamma]9V[delta]2 T Cell Receptor Interactions with a Surface F1-ATPase-Related Structure and Apolipoprotein A-I. Immunity 22: 71-80.
34. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, et al. (1991) Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 47: 285-290.
35. Creaney J, McLaren BM, Stevenson S, Musk AW, de Klerk N, et al. (2001) p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84: 52-56.
36. Lock RA, Cordwell SJ, Coombs GW, Walsh BJ, Forbes GM, (2001) Proteome analysis of Helicobacter pylori: major proteins of type strain NCTC 11637. Pathology 33: 365-374.